Skip to Content

尊敬的客户:

目前国际形势复杂多变,关税政策尚不明朗,这可能对我们的产品价格产生一定影响。在此情况下,我们希望就订单事宜与您进行友好沟通。

基于当前的不确定性,如果您选择在此期间下单,我们将保留根据实际情况调整价格的权利。同时,我们也理解市场变化可能给您带来的困扰,因此如果在订单实际发货前因关税政策变动导致价格出现较大波动,默克将与您进行协商讨论并视情况对订单进行调整或取消。

We are planning system maintenance between Friday, Apr 18 at 9:00 PM CDT and Saturday, Apr 19 at 9:00 AM CDT. This will impact both web and offline transactions, including online orders, quotes, price and availability checks, and order status inquiries. We apologize for any inconvenience.

关于应对近期政策变化的重要更新,请点击此处查看详情。

Merck
CN
  • COVID-19 patients exhibit unique transcriptional signatures indicative of disease severity.

COVID-19 patients exhibit unique transcriptional signatures indicative of disease severity.

Frontiers in immunology (2022-10-04)
Andrea R Daamen, Prathyusha Bachali, Catherine A Bonham, Lindsay Somerville, Jeffrey M Sturek, Amrie C Grammer, Alexandra Kadl, Peter E Lipsky
ABSTRACT

COVID-19 manifests a spectrum of respiratory symptoms, with the more severe often requiring hospitalization. To identify markers for disease progression, we analyzed longitudinal gene expression data from patients with confirmed SARS-CoV-2 infection admitted to the intensive care unit (ICU) for acute hypoxic respiratory failure (AHRF) as well as other ICU patients with or without AHRF and correlated results of gene set enrichment analysis with clinical features. The results were then compared with a second dataset of COVID-19 patients separated by disease stage and severity. Transcriptomic analysis revealed that enrichment of plasma cells (PCs) was characteristic of all COVID-19 patients whereas enrichment of interferon (IFN) and neutrophil gene signatures was specific to patients requiring hospitalization. Furthermore, gene expression results were used to divide AHRF COVID-19 patients into 2 groups with differences in immune profiles and clinical features indicative of severe disease. Thus, transcriptomic analysis reveals gene signatures unique to COVID-19 patients and provides opportunities for identification of the most at-risk individuals.

MATERIALS
Product Number
Brand
Product Description

Millipore
MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A - Immunology Multiplex Assay
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
100 μL
Estimated to ship on April 21, 2025
Details...
CN¥5,294.29
0.2 mL
Please contact Customer Service for Availability
CN¥7,940.75